CD8A and glioblastoma: The CD8+/Foxp3+ T cell ratio, which is positively related to the survival outcomes in GBM mice, was significantly high with the A2-APM treatment group being 5.85- and 1.77-fold greater than the saline and free aPD-L1 groups, respectively.